Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: A Bayesian pharmacokinetic approach

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4888-4898

  Salinger, David H ^a,b   McCune, Jeannine S ^a,c   Ren, Aaron G ^a   Shen, Danny D ^a,c   Slattery, John T ^a,c   Phillips, Brian ^c   McDonald, George B ^a,c   Vicini, Paolo ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYETHYLPHOSPHORAMIDE MUSTARD; CYCLOPHOSPHAMIDE; HYDROXYCYCLOPHOSPHAMIDE; PHOSPHORAMIDE MUSTARD; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CANCER; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SIMULATION;

BAYES THEOREM; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; PHOSPHORAMIDE MUSTARDS; SOFTWARE; TRANSPLANTATION CONDITIONING;

EID: 33748339220     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2079     Document Type: Article

References (33)

1. McCune JS, Slattery JT. Pharmacological considerations of primary alkylators. In: Andersson B, Murray D, editors. Clinically relevant resistance in cancer chemotherapy. Boston: Kluwer Academic; 2002. p. 323-37.
2. McDonald GB, Slattery JT, Bouvier ME, et al. CY metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-8.
3. Moore MJ. Clinical pharmacokinetics of CY. Clin Pharmacokinet 1991;20:194-208.
4. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of CY to 4-hydroxyCY and deschloroethylCY in human liver microsomes. Cancer Res 1997;57:4229-35.
5. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992;43:2453-69.
6. Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV. CY metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:455-60.
7. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:441-59.
8. Taylor JW, Murphy MJ, Berg MJ, Perry PJ, Lyon LW, Ludden TM. Phenytoin dosage requirements and pharmacokinetic variables. Clin Pharmacokinet 1983;2:253-7.
9. Vozeh S, Uematsu T, Ritz R, et al. Computer-assisted individualized lidocaine dosage: clinical evaluation and comparison with physician performance. Am Heart J 1987;113:928-33.
10. Rousseau A, Marquet P, Debord J, Sabot C, Lachatre G. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000;38:315-53.
11. Huitema AD, Mathot RA, Tibben MM, Rodenhuis S, Beijnen JH. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 2001;23:650-7.
12. de Jonge ME, van den Bongard HJ, Huitema AD, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004;10:2237-44.
13. de Jonge ME, Huitema AD, Tukker AC, van Dam SM, Rodenhuis S, Beijnen JH. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005;11:273-83.
14. Qiu R, Yao A, Vicini P, et al. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the CY metabolite carboxyethylphosphoramide mustard. Clin Pharmacol Ther 2004;76:270-80.
15. McDonald GB, McCune JS, Batchelder AL, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005;78:298-308.
16. R Development Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2005. ISBN 3-900051-07-0.
17. Lapsley M, Ripley BD. RODBC: ODBC database access. R package version 1.1-3; 2005.
18. Genz A, Bretz F, Hothorn T. MVTNORM: multivariate normal and T distribution. R package version 0.7-1; 2004.
19. Setzer RW. ODEsolve: solvers for ordinary differential equations. R package version 0.5-12; 2004.
20. Hassan M, Svensson US, Ljungman P, et al. A mechanism-based pharmacokinetic enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 1999;48:669-77.
21. Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm 1984;12:545-58.
22. Jelliffe RW, Schumitzky A. Modeling, adaptive control, and optimal drug therapy. Med Prog Technol 1990;16:95-110.
23. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
24. Duffull SB, Kirkpatrick CMJ, Green B, Holoford NHG. Analysis if population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat 2005;15:53-73.
25. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-611.
26. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16:2297-8.
27. Egorin MJ. Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. J Clin Oncol 2003;21:182-3.
28. Miller AA. Body surface area in dosing anticancer agents: scratch the surface! J Natl Cancer Inst 2002;94:1822-3.
29. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-8.
30. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000;39:155-65.
31. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
32. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 2005;23:413-21.
33. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004;22:3357-65.